HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
RARE
Ultragenyx Pharmaceutical Inc
Healthcare Biotechnology · California, USA · Reports in usd
Market Cap: $2.31B
Market Cap
$2.31B
Enterprise Val
$2.89B
P/E Ratio
-4.03
P/B Ratio
-26.60
Trailing PEG (1Y)
0.56
As Of
Apr 26, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value-$73.0M
Gross Margin85.84%
Profit Margin85.84%
Return on Equity-1,169.35%
Return on Assets-43.07%
Current Ratio2.48
Debt/Equity-14.39
LT Debt/Equity-13.46
Revenue Per Share2.15

Income Statement

Dec 31, 2025
Revenue$207.3M
Cost of Revenue$29.3M
Gross Profit$177.9M
R&D$203.3M
SG&A$87.9M
Operating Expenses$291.2M
Operating Income-$113.3M
Interest Expense$0.00
Tax Expense$870.0K
Net Income-$128.6M
EPS (Basic)$-1.28
EPS (Diluted)$-1.28
EBIT-$127.7M
EBITDA-$118.9M
Consolidated Income-$128.6M
Non-Controlling Interests$0.00

Balance Sheet

Dec 31, 2025
Cash & Equivalents$421.0M
Accounts Receivable$158.0M
Inventory$52.0M
Current Assets$951.0M
LT Investments$57.0M
Property, Plant & Equipment$244.0M
Intangibles$220.0M
Non-Current Assets$581.0M
Total Assets$1.53B
Accounts Payable$31.0M
Current Debt$81.0M
Current Liabilities$384.0M
LT Debt$1.17B
Non-Current Liabilities$1.22B
Total Liabilities$1.61B
Total Debt$1.25B
Retained Earnings-$4.53B
Shareholder Equity-$87.0M
Shares Outstanding96,477,569

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow-$99.8M
Investing Cash Flow-$72.2M
Financing Cash Flow$394.2M
CapEx-$938.0K
Free Cash Flow-$100.8M
Depreciation & Amort.$8.8M
Stock-Based Comp$37.3M
Acquisitions / Disposals$0.00
Investment Activity-$71.6M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$2.2M
Dividends Paid$0.00
Net Change in Cash$221.5M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h